Lindus Health offers comprehensive end-to-end clinical trial services for life science companies, utilizing a technology-first approach and a proprietary software platform called Citrus to expedite the delivery of new treatments to patients. Pulse 2.0 interviewed Lindus Health co-founder Meri Beckwith to gain a deeper understanding of the company.
Meri Beckwith’s Background
Could you tell me more about your background? Beckwith said:
“Before founding Lindus Health, I worked as a venture capital investor and partnered with digital health and biotechnology companies. My inspiration to launch Lindus Health came from firsthand experience as a clinical trial participant.I’d been a part of several clinical trials—for ketamine, eosinophilic esophagitis, and even Phase III COVID-19 vaccine trials. Those experiences opened my eyes to how frustratingly slow and inefficient the process can be. Trials are often bogged down by delays, which means patients wait longer for life-saving treatments, and costs for researchers spiral.I realized the system could be fundamentally better by placing the patient experience at the forefront, which is what drove me to start Lindus Health.”
“As the co-CEO Lindus Health, my primary responsibility is to help drive our mission.. A key part of my role is engaging with sponsors directly to help set their trials up for success, and ensuring our teams are doing the same.
Favorite Memory
What has been your favorite memory working for the company so far? Beckwith reflected:
“Wrapping up our first end-to-end trial and seeing firsthand the impact of a well-run, patient-centric approach. I was genuinely surprised by how many patients took the time to share thoughtful feedback—not just about the intervention, but about the care they received and their overall experience. This was a powerful reminder that we often underestimate how meaningful it is for patients to feel heard and included in the research process.Hearing directly from participants about how easy and transparent the process was reinforced why we do what we do: to create better trials that drive better outcomes for patients.”
Core Products
What are the company’s core products and features? Beckwith explained:
“We’re an All-in-One CRO. That means we handle everything—study startup, patient recruitment, site selection, monitoring, data management, and biostatistics. For recruitment, we use multiple tactics tailored to each trial, from database screening of 40 million electronic health records to digital advertising and community-based outreach.
We’ve also designed our own proprietary trial management technology—Citrus. One of the most common pain points in clinical operations is data and system fragmentation. With us, instead of sponsors having to use multiple platforms for essential tools—electronic data capture (EDC), the clinical trial management system (CTMS), patient pre-screening, eConsent, and many others—Citrus houses all of these technologies in one place. By centralizing everything, we can monitor trials in real time, automate biostatistics, and ensure data is standardized and ready for analysis.”
Challenges Faced
What challenges have Beckwith and the team faced in building the company? Beckwith acknowledged:
There’s been a clear slowdown in funding for private biotech, which means fewer trials being launched,” Beckwith acknowledged. “To adapt, we’ve deepened partnerships with established pharma and digital therapeutics companies. That’s helped us maintain momentum while also broadening the therapeutic areas we cover.
Evolution Of The Company’s Technology
How has the company’s technology evolved? Beckwith noted:
“Our technology has evolved substantially since we began, moving from a simple electronic data capture system in the early days of Lindus, to what is now Citrus—our unified platform for all things trial management.
“We’re one of the first CROs in the industry to leverage AI technologies like machine learning (ML) to our advantage. Our home-grown AI and automation technologies can predict trial success based on historical trial outcomes, proactively recognize and address recruitment bottlenecks before they occur, optimize site selection, monitor data in real time to spot data anomalies as they arise. Most CROs often catch issues retrospectively, which significantly slows operations. With our integrated technology, we can act immediately to improve both patient safety and trial efficiency.”
Significant Milestones
What have been some of the company’s most significant milestones? Beckwith cited:
”We’ve introduced 11 specialized CRO offerings to address the unique challenges in areas such as women’s health, metabolic health, and cardiovascular health. To date, we have successfully operated over 40 end-to-end clinical trials—impacting various market segments like psychiatry, diagnostics, and respiratory health—with more than 36,000 patients enrolled in North America and Europe.”
“Additionally, we recently raised $55 million in Series B funding led by Balderton Capital, with support from Visionaries Club and existing investors Creandum, Firstminute, and Seedcamp. This funding is evidence that what we’re doing is working, and we’re humbled to continue to create monumental change in the way trials are run.
Customer Success Stories
When asking Beckwith about customer success stories, he highlighted:
Our study with Pharmanovia really stands out to us. “Recruiting patients for Chloral Hydrate research was extremely difficult, as it’s usually only in secondary care. By rethinking recruitment and using digital media in primary care, we streamlined the process.
Despite the challenges, the trial hit its goals quickly and provided critical real-world evidence. The Medicines and Healthcare products Regulatory Agency (MHRA) originally projected an eight-month review period before we can even initiate the study. We were able to rewrite that narrative thanks to our network of industry leaders and reduce it to just three months. But we still needed to recruit patients quickly. Within just five months, we enrolled 90 patients while maintaining 86% retention. We had research nurses, sleep specialists, and doctors to work with patients directly in the trial.
Total Addressable Market
What total addressable market (TAM) size is the company pursuing? Beckwith assessed:
“The CRO services market was valued at $112 billion in 2024, and is expected to reach $166 billion by 2029, rising at a CAGR of 8.2%, according to a report from Research and Markets.”
Differentiation From The Competition
What differentiates the company from its competition? Beckwith affirmed:
“Our pricing model is fixed and milestone-based, so our sponsors pay when we deliver. CROs are notorious for billing for extraneous hours worked—even when extra work is needed as a result of their own errors. Our model aligns incentives so when sponsors win, so do we.”
Future Company Goals
What are some of the company’s future goals? Beckwith concluded:
“Our mission will always be our motivator—delivering radically faster, more reliable clinical trials so patients can get the essential treatments they need sooner. In addition to exploring other avenues for AI and automation integration, we’re actively improving our AI to optimize real-time data monitoring and biostatistical analysis. By 2030, we want Lindus Health to be the default choice for companies running clinical research—just as we already are in certain sectors today.”
